<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00690937</url>
  </required_header>
  <id_info>
    <org_study_id>ECS00107</org_study_id>
    <secondary_id>ELLS</secondary_id>
    <nct_id>NCT00690937</nct_id>
  </id_info>
  <brief_title>A Multicenter, Active and Placebo-controlled Study of Enteric Coated Sevelamer in Patients With Mild to Moderate Hypercholesteremia</brief_title>
  <acronym>Sevelamer ECS</acronym>
  <official_title>A Multicenter, Single-blind, Active and Placebo-controlled, Parallel-group, Randomized Study of Two Dosing Regimens of Enteric Coated Sevelamer in Patients With Mild to Moderate Hypercholesterolemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Manipal Acunova Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A total of 120 patients will be entered in this study to assess the safety and efficacy of
      enteric coated sevelamer (ECS) to lower LDL cholesterol. Patients will be randomized into two
      active treatment groups, two placebo groups and one active control group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, randomized, single blind, active and placebo-controlled,
      parallel-group, multi-center study.

      Two groups of ECS consisting of 3 and 6 tablets/day (n=30), two placebo groups of 3 and 6
      tablets/day (n=15 each) and one active control group of colesevelam 6 tablets/day (n=30). The
      study is being conducted solely in India and there will be a total of 6-8 sites.

      The safety parameters are:

        -  Serious adverse events SAEs

        -  Treatment and non-treatment emergent AEs

        -  Physical exams and vital signs

        -  Clinical safety laboratories

      The efficacy parameters include a fasting lipid profile:

        -  Low density lipoproteins (LDL)

        -  Total cholesterol

        -  High density lipoproteins (HDL)

        -  Triglycerides
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary safety endpoints are: The type and number of AEs and proportion of patients with AEs.</measure>
    <time_frame>throughout study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of clinical laboratory parameters including blood chemistry, liver function tests, and renal function tests and hematology (CBC).</measure>
    <time_frame>throughout study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The primary efficacy endpoint is: The percent change in LDL cholesterol from baseline.</measure>
    <time_frame>From baseline to Day 42</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The secondary efficacy endpoints are: the absolute change in LDL cholesterol from baseline.</measure>
    <time_frame>From baseline to Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percent change in total cholesterol, HDL cholesterol and triglycerides from baseline.</measure>
    <time_frame>From baseline to Day 42</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>1 ECS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 ECS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 Colesevelam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active control treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo matched to low dose treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo matched to high dose treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enteric coated sevelamer</intervention_name>
    <description>Drug treatment</description>
    <arm_group_label>1 ECS</arm_group_label>
    <other_name>ECS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enteric coated sevelamer</intervention_name>
    <description>Drug treatment</description>
    <arm_group_label>2 ECS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colesevelam Cholestagel</intervention_name>
    <description>Drug comparator</description>
    <arm_group_label>3 Colesevelam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>4 Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>5 Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females 18 years of age or older

          -  Clinical diagnosis of mild to moderate hypercholesterolemia 1)LDL cholesterol greater
             than or equal to 130 mg/dL and less than or equal to 220 mg/dL 2) Triglycerides less
             than or equal to 300 mg/dL

        Exclusion Criteria:

          -  Women who are pregnant or lactating.

          -  Patients using other lipid-lowering medications during .

          -  Patients with unstable medical conditions and/or comorbidities
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Genzyme, a Sanofi Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Diacon Hospital and Research Center</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M S Ramaiah Medical College and Memorial Hospital</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Appollo first Med Hospital</name>
      <address>
        <city>Chennai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associates in Clinical Endocronolgy Education &amp; Research (ACEER)</name>
      <address>
        <city>Chennai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Care Hospital</name>
      <address>
        <city>Hyderabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes Endocrine Nutrition Management and Research Center</name>
      <address>
        <city>Mumbai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P D Hinduja National Hospital and Medical Research Centre</name>
      <address>
        <city>Mumbai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indraprastha Apollo Hospitals</name>
      <address>
        <city>New Delhi</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 3, 2008</study_first_submitted>
  <study_first_submitted_qc>June 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2008</study_first_posted>
  <last_update_submitted>March 17, 2014</last_update_submitted>
  <last_update_submitted_qc>March 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hypercholesterolemia, bile acid sequestrant, LDL-cholesterol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sevelamer</mesh_term>
    <mesh_term>Colesevelam Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

